Nutex Health vs Priority Technology
NUTX and PRTH side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NUTX and PRTH compare
Nutex Health is the larger company, worth 2.0 times as much as Priority Technology ($1.3B against $651M).
On earnings, Nutex Health is cheaper: it trades at 8.1× trailing earnings, against 16.1× for Priority Technology.
Priority Technology grew revenue faster over the last twelve months (10.1% versus −18.8% for Nutex Health).
Nutex Health scores higher on the StockData Score (15 against 9 for Priority Technology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NUTX | PRTH |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $651M |
| Share price | $189.19 | $7.90 |
| Change, 1 year | 59.2% | 41.8% |
| Change, 5 years | −69.6% | 28.5% |
| Beta (5Y) | 1.86 | 1.01 |
| Employees | 944 | 1,200 |
| StockData Score | ||
| Total score | 15 (better) | 9 |
| Valuation score | 4 | 4 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.1× (better) | 16.1× |
| P/S | 1.6× | 0.6× (better) |
| P/B | 3.0× | – |
| EV/EBITDA | 3.6× (better) | 7.4× |
| P/FCF | 5.2× (better) | 6.0× |
| FCF yield | 19.1% (better) | 16.7% |
| Fair value | $570.15 | $13.98 |
| Margin of safety | 66.8% (better) | 43.5% |
| Growth | ||
| Revenue growth (TTM) | −18.8% | 10.1% (better) |
| Revenue growth, 5Y average | 26.1% (better) | 18.7% |
| Net income growth (TTM) | 36.5% | – |
| EPS growth (TTM) | 21.2% (better) | −7.5% |
| EPS growth, 5Y average | −17.2% | 12.3% (better) |
| Profitability | ||
| Gross margin | 47.8% (better) | 39.1% |
| Operating margin | 39.0% (better) | 13.2% |
| Net margin | 20.7% | – |
| FCF margin | 31.1% (better) | 10.6% |
| Return on equity | 43.8% | – |
| Return on invested capital | 117% (better) | 12.7% |
| Financial health | ||
| Debt / equity | 0.10 | – |
| Net debt / EBITDA | −0.62 | 4.30 (better) |
| Interest coverage | 16.2× (better) | 1.6× |
| Current ratio | 4.76 (better) | 1.10 |
| Altman Z-score | 3.75 (better) | 0.74 |
| Piotroski F-score | 7 | – |
| Dividends and buybacks | ||
| Buyback yield | 4.3% | – |
| Shareholder yield | 4.3% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 42.9% | 23.6% |
| Held by insiders | – | 59.7% |
| Insider net buying, 12 months | $2.2K (better) | −$23.8K |
Go deeper
- NUTX stock overview
- NUTX income statement
- NUTX valuation and score
- PRTH stock overview
- PRTH income statement
- PRTH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.